UpdatesPress Release
Infinium Pharmachem has commissioned its new contrast media raw materials facility, a key forward integration.
Infinium Pharmachem LimitedINFINIUM · Filed with the exchange
This move targets ₹100 Cr annual revenue within 3 years at ~30% EBITDA margin, expected to boost blended EBITDA to ~20%.
No comments yet. Be the first.